Renal Cell Cancer clinical trials

Explore recruiting renal cell cancer clinical trials.

Recruiting renal cell cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Renal Cell Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Cabozantinib and Nivolumab among older patients with renal-cell carcinoma, a prospective cohort with geriatric, pharmacologic and patient-reported-outcome evaluation (CABOLD)

France

Therapeutic use (Phase IV) EU CTIS Study details

Prospective, randomized, neoadjuvant phase II study with combination immuno-oncology in primary clear cell renal cell cancer at risk for recurrence or distant metastases (NESCIO-trial; M21NSC; CA209-6DJ)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

Germany, Ireland, Hungary, Austria, Spain, Netherlands +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Denmark, Finland, France, Spain, Netherlands, Poland +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Germany, France, Denmark, Sweden, Finland, Romania +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

C6461008 - AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

Germany, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Renal Cell Cancer trials by city

Renal Cell Cancer in Toronto Renal Cell Cancer in Vancouver Renal Cell Cancer in Montreal Renal Cell Cancer in Calgary Renal Cell Cancer in Edmonton Renal Cell Cancer in Ottawa Renal Cell Cancer in Winnipeg Renal Cell Cancer in Quebec City Renal Cell Cancer in Hamilton Renal Cell Cancer in Kitchener Renal Cell Cancer in London Renal Cell Cancer in Halifax Renal Cell Cancer in New York Renal Cell Cancer in Los Angeles Renal Cell Cancer in Chicago Renal Cell Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease